Bio-Rad Laboratories Class A

BIO

Market cap $7.92B

I assign a "Buy" rating to Bio-Rad Laboratories, citing activist involvement. Elliott's entry signals meaningful re-rating potential, assuming further operational improvements; BIO is already shifting M&A focus to revenue-generating bolt-ons and rationalizing R&D spend. The potential monetization of BIO's Sartorius stake, worth over $5 billion, appears more likely with Elliott's involvement, since the activist is also a shareholder of Sartorius.

Bio-Rad Laboratories offers high profitability and a liquid balance sheet with a current ratio above 5x. Charles River Laboratories International maintains a leading scale in drug discovery services with over 19,000 employees globally.

Biometric authentication provider BIO-key's (BKYI) CEO will participate in a webcast fireside chat at Maxim Group's Defense Tech Conf. 6-25 at 4pm, track 2

Bio-Rad Laboratories, Inc. (BIO) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Bio-Rad Laboratories, Inc. (BIO) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Activist investor Elliott Investment Management has built a sizeable stake ​in U.S. diagnostics supplier Bio-Rad Laboratories , and plans ‌to push the company to boost its underperforming stock price, the Wall Street Journal reported on Sunday.

Elliott also has a stake in German lab-equipment supplier Sartorius, where Bio-Rad is also an investor.

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company will participate in the following upcoming investor conferences: 2026 RBC Capital Markets Global Healthcare Conference Format: Fireside chat and one-on-one investor meetings Participants: Roop K. Lakkaraju, Chief Financial Officer Date and Time: Tuesday, May 19, 2026, at 8:30 AM Eastern Time; a live webc.

APA Corporation was the top contributor during the quarter. SLB Limited advanced during the quarter as investors grew more confident. Fiserv declined over the quarter despite reporting inline earnings results.

Explore how Bio-Rad's (BIO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.